CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Cabozantinib (Cabometyx) for Hepatocellular Carcinoma - Details

Project Number PC0186-000
Brand Name Cabometyx
Generic Name Cabozantinib
Strength 20 mg, 40 mg & 60 mg
Tumour Type Gastrointestinal
Indication Hepatocellular Carcinoma
Funding Request For the treatment of Hepatocellular Carcinoma (HCC) in adults after prior therapy
Review Status Complete
Pre Noc Submission Yes
NOC Date November 8, 2019
Manufacturer Ipsen Biopharmaceuticals Canada Inc.
Sponsor Ipsen Biopharmaceuticals Canada Inc.
Submission Date October 16, 2019
Submission Deemed Complete October 30, 2019
Submission Type Initial
Prioritization Requested
Stakeholder Input Deadline ‡ October 30, 2019
Check-point meeting January 8, 2020
pERC Meeting March 19, 2020
Initial Recommendation Issued April 2, 2020
Feedback Deadline ‡ April 17, 2020
Final Recommendation Issued April 22, 2020
Notification to Implement Issued May 7, 2020
Therapeutic Area HCC
Recommendation Type Reimburse with clinical criteria and/or conditions

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.